User login
Expert Update on Acute Bacterial Skin and Skin Structure Infection Treatment Options in the Community Setting
Click here to access this content now
Click here to access this content now
Click here to access this content now
Advances in Diabetes and Cardiovascular Care
Real-World Experience With Automated Insulin Pumps
Continuous Blood Glucose Monitoring for T2DM
Statin-Induced Adverse Effects
Long QT and Cardiac Arrest After Pulmonary Edema
And more online
• Clinical Impact of U-500 Insulin Initiation
• Diabetes Self-Management Education
• SGLT2 Inhibitors, T2DM, and Heart Failure
• Alirocumab Use in Statin-Intolerant Veterans
• K Pneumoniae-Induced Aortitis
Real-World Experience With Automated Insulin Pumps
Continuous Blood Glucose Monitoring for T2DM
Statin-Induced Adverse Effects
Long QT and Cardiac Arrest After Pulmonary Edema
And more online
• Clinical Impact of U-500 Insulin Initiation
• Diabetes Self-Management Education
• SGLT2 Inhibitors, T2DM, and Heart Failure
• Alirocumab Use in Statin-Intolerant Veterans
• K Pneumoniae-Induced Aortitis
Real-World Experience With Automated Insulin Pumps
Continuous Blood Glucose Monitoring for T2DM
Statin-Induced Adverse Effects
Long QT and Cardiac Arrest After Pulmonary Edema
And more online
• Clinical Impact of U-500 Insulin Initiation
• Diabetes Self-Management Education
• SGLT2 Inhibitors, T2DM, and Heart Failure
• Alirocumab Use in Statin-Intolerant Veterans
• K Pneumoniae-Induced Aortitis
A Family Physician's Introduction to Lifestyle Medicine
Click here to access this content now
Click here to access this content now
Click here to access this content now
Atopic Dermatitis: A supplement to Dermatology News
- PATIENT SATISFACTION WITH TREATMENT
- REDUCING ITCH
- BURDEN OF DISEASE IN BLACK PATIENTS
- BATHING RECOMMENDATIONS
- PATIENT SATISFACTION WITH TREATMENT
- REDUCING ITCH
- BURDEN OF DISEASE IN BLACK PATIENTS
- BATHING RECOMMENDATIONS
- PATIENT SATISFACTION WITH TREATMENT
- REDUCING ITCH
- BURDEN OF DISEASE IN BLACK PATIENTS
- BATHING RECOMMENDATIONS
Best of 2021: The RA Report
Best of 2021
The RA Report
A Supplement to Rhematology News
- Treatment responders show unique differences in gut microbiome
- Gene variant confirmed as strong predictor of interstitial lung disease
- Multiple comorbidities lower odds of disease control
- Blood-based test aims to predict nonresponse to TNF inhibitors
- Evidence grows for food as treatment
- Oral steroids plus proton pump inhibitors raise osteoporotic fracture risk
- Novel study links air pollution to increased risk of flares
Best of 2021
The RA Report
A Supplement to Rhematology News
- Treatment responders show unique differences in gut microbiome
- Gene variant confirmed as strong predictor of interstitial lung disease
- Multiple comorbidities lower odds of disease control
- Blood-based test aims to predict nonresponse to TNF inhibitors
- Evidence grows for food as treatment
- Oral steroids plus proton pump inhibitors raise osteoporotic fracture risk
- Novel study links air pollution to increased risk of flares
Best of 2021
The RA Report
A Supplement to Rhematology News
- Treatment responders show unique differences in gut microbiome
- Gene variant confirmed as strong predictor of interstitial lung disease
- Multiple comorbidities lower odds of disease control
- Blood-based test aims to predict nonresponse to TNF inhibitors
- Evidence grows for food as treatment
- Oral steroids plus proton pump inhibitors raise osteoporotic fracture risk
- Novel study links air pollution to increased risk of flares
ObGyns—Leaders, not followers, in cervical cancer screening
Advancing Maternal-Fetal Immunology by Unlocking New Insights into Immune Pathways
Click here to read more
Click here to read more
Click here to read more
Newborn Screening for Spinal Muscular Atrophy in the United States
Click here to read the supplement
Newborn screening for spinal muscular atrophy (SMA) is essential to achieve optimal outcomes for patients with SMA by facilitating early identification and treatment before the onset of irreversible motor neuron loss.
Click here to read the supplement
Newborn screening for spinal muscular atrophy (SMA) is essential to achieve optimal outcomes for patients with SMA by facilitating early identification and treatment before the onset of irreversible motor neuron loss.
Click here to read the supplement
Newborn screening for spinal muscular atrophy (SMA) is essential to achieve optimal outcomes for patients with SMA by facilitating early identification and treatment before the onset of irreversible motor neuron loss.
2021 Rare Diseases Report: Cancers
INTRODUCTIONS
Editor's Note: Looking forward
By Mark S. Lesney, PhD
The Rare Diseases Report: Cancers looks to the future from trial design to treatment for some of the most underserved diseases and patient populations.
NORD: Approaching rare cancers through a diversity lens
By Rebecca Aune and Debbie Drell
NORD advocates for all rare disease patients, no matter their race, ethnicity, religion, color, national origin, age, disability, sexual orientation, gender identity, etc.
CLINICAL REVIEWS
Precision medicine: A new approach to AML, other blood cancers
By Caleb Rans, PHARMD
Precision medicine makes groundbreaking strides in treating myeloid malignancies by integrating individual molecular data into patient care.
Coping with a shattered immune system: COVID and beyond
By Christine Kilgore
Questions abound about vaccine timing and the immune response in hematologic malignancies.
Racial disparities in blood cancer treatment
By Roxanne Nelson
An increasing number of studies have documented racial disparities among the study, treatment, and management of hematologic malignancies.
Overcoming obstacles in rare GU cancers
By Will Pass
Investigators are meeting the challenge of dealing with rare genitourinary cancers through collaboration, novel treatment efforts, and clinical trial design.
Mesothelioma trials: Moving toward improved survival
By Andrew D. Bowser
New and emerging therapy developments show promise of extended survival for select patients.
Metastatic uveal melanoma -- new drugs in pipeline, but prognoses still grim
By Randy Dotinga
As many as 50% of patients with this rare form of eye cancer develop tumors elsewhere.
Meeting the unmet need in multiple myeloma
By Walter Alexander
Multiple myeloma remains an incurable plasma cell disorder with near-certain relapse after successful treatment.
Rhabdomyosarcoma: Adaptive therapy borrows from nature
By Neil Osterweil
Researchers are applying evolutionary principles to the treatment of childhood, fusion-positive rhabdomyosarcoma.
INTRODUCTIONS
Editor's Note: Looking forward
By Mark S. Lesney, PhD
The Rare Diseases Report: Cancers looks to the future from trial design to treatment for some of the most underserved diseases and patient populations.
NORD: Approaching rare cancers through a diversity lens
By Rebecca Aune and Debbie Drell
NORD advocates for all rare disease patients, no matter their race, ethnicity, religion, color, national origin, age, disability, sexual orientation, gender identity, etc.
CLINICAL REVIEWS
Precision medicine: A new approach to AML, other blood cancers
By Caleb Rans, PHARMD
Precision medicine makes groundbreaking strides in treating myeloid malignancies by integrating individual molecular data into patient care.
Coping with a shattered immune system: COVID and beyond
By Christine Kilgore
Questions abound about vaccine timing and the immune response in hematologic malignancies.
Racial disparities in blood cancer treatment
By Roxanne Nelson
An increasing number of studies have documented racial disparities among the study, treatment, and management of hematologic malignancies.
Overcoming obstacles in rare GU cancers
By Will Pass
Investigators are meeting the challenge of dealing with rare genitourinary cancers through collaboration, novel treatment efforts, and clinical trial design.
Mesothelioma trials: Moving toward improved survival
By Andrew D. Bowser
New and emerging therapy developments show promise of extended survival for select patients.
Metastatic uveal melanoma -- new drugs in pipeline, but prognoses still grim
By Randy Dotinga
As many as 50% of patients with this rare form of eye cancer develop tumors elsewhere.
Meeting the unmet need in multiple myeloma
By Walter Alexander
Multiple myeloma remains an incurable plasma cell disorder with near-certain relapse after successful treatment.
Rhabdomyosarcoma: Adaptive therapy borrows from nature
By Neil Osterweil
Researchers are applying evolutionary principles to the treatment of childhood, fusion-positive rhabdomyosarcoma.
INTRODUCTIONS
Editor's Note: Looking forward
By Mark S. Lesney, PhD
The Rare Diseases Report: Cancers looks to the future from trial design to treatment for some of the most underserved diseases and patient populations.
NORD: Approaching rare cancers through a diversity lens
By Rebecca Aune and Debbie Drell
NORD advocates for all rare disease patients, no matter their race, ethnicity, religion, color, national origin, age, disability, sexual orientation, gender identity, etc.
CLINICAL REVIEWS
Precision medicine: A new approach to AML, other blood cancers
By Caleb Rans, PHARMD
Precision medicine makes groundbreaking strides in treating myeloid malignancies by integrating individual molecular data into patient care.
Coping with a shattered immune system: COVID and beyond
By Christine Kilgore
Questions abound about vaccine timing and the immune response in hematologic malignancies.
Racial disparities in blood cancer treatment
By Roxanne Nelson
An increasing number of studies have documented racial disparities among the study, treatment, and management of hematologic malignancies.
Overcoming obstacles in rare GU cancers
By Will Pass
Investigators are meeting the challenge of dealing with rare genitourinary cancers through collaboration, novel treatment efforts, and clinical trial design.
Mesothelioma trials: Moving toward improved survival
By Andrew D. Bowser
New and emerging therapy developments show promise of extended survival for select patients.
Metastatic uveal melanoma -- new drugs in pipeline, but prognoses still grim
By Randy Dotinga
As many as 50% of patients with this rare form of eye cancer develop tumors elsewhere.
Meeting the unmet need in multiple myeloma
By Walter Alexander
Multiple myeloma remains an incurable plasma cell disorder with near-certain relapse after successful treatment.
Rhabdomyosarcoma: Adaptive therapy borrows from nature
By Neil Osterweil
Researchers are applying evolutionary principles to the treatment of childhood, fusion-positive rhabdomyosarcoma.
